Gilead Sciences (GILD) Stock Forecast & Price Target
Score
Gilead Sciences, Inc. price target
| GILD | |
|---|---|
| Low | $126.00 |
| Average | $165.38 |
| High | $196.00 |
| Upside vs current price | -1.6% |
The average target of $165.38 is -1.6% versus the current GILD price of $168.08.
Gilead Sciences, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 6 |
| Buy | 16 |
| Hold | 5 |
| Sell | 0 |
| Strong sell | 1 |
| Consensus | Buy |
28 analysts cover GILD.
Gilead Sciences, Inc. EPS and revenue estimates
GILD shows the next fiscal years with at least three analysts: 2026 EPS $-0.82, 2027 EPS $10.10. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.82 | $31.25B |
| 2027 | $10.10 | $33.47B |
Is Gilead Sciences, Inc. a buy or sell?
Of the 28 analysts covering Gilead Sciences, Inc., 22 rate it a buy (6 strong buy and 16 buy), 5 rate it a hold, and 1 rates it a sell (0 sell and 1 strong sell).
The GILD consensus label is Buy, beside 22 buy-side ratings and 1 sell-side ratings.
The average target of $165.38 implies -1.6% versus the current price of $168.08.
Those 28 ratings on GILD are a headcount, and the label on file is Buy.
Reading the Gilead Sciences, Inc. forecast
The GILD target range is wide: $126.00 at the low end, $165.38 in the middle, and $196.00 at the top.
Set next to the $168.08 GILD quote, that average is -1.6%.
Ratings on the Gilead Sciences, Inc. cluster: 22 of 28 analysts are on the buy side, 5 are at hold, and 1 is on the sell side, and the published consensus is Buy.
Recent GILD revisions are two-sided: 0 upgrades and 1 downgrades.
The average GILD target over the last month is $173.11, above the $167.17 average of the last quarter.
28 analysts publish on GILD, so one note does not swing the average by itself.
Gilead Sciences, Inc. forecast questions
What is the GILD price target?
The published range for GILD is $126.00 to $196.00, with an average of $165.38. That average is -1.6% versus the current price of $168.08.
Is Gilead Sciences, Inc. a buy or sell?
Of the 28 analysts covering Gilead Sciences, Inc., 22 rate it a buy, 5 rate it a hold, and 1 rates it a sell. The consensus is Buy, and the GILD headcount is 22 buy, 5 hold, and 1 sell.
What is the EPS estimate for Gilead Sciences, Inc.?
Analyst EPS estimates for Gilead Sciences, Inc.: 2026 $-0.82, 2027 $10.10.
What is the revenue estimate for Gilead Sciences, Inc.?
Analyst revenue estimates for Gilead Sciences, Inc.: 2026 $31.25B, 2027 $33.47B.
How many analysts cover GILD?
28 analysts cover GILD. Their consensus on GILD is Buy, across those 28.